Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study

SIMPLE SUMMARY: Immunotherapy with atezolizumab plus bevacizumab as well as tremelimumab plus durvalumab has recently become the preferred first-line treatment for advanced hepatocellular carcinoma (HCC). Lenvatinib was initially approved as a first-line treatment, but little is known about its effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Mathias E., Gile, Jennifer J., Storandt, Michael H., Jin, Zhaohui, Zemla, Tyler J., Tran, Nguyen H., Mahipal, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571707/
https://www.ncbi.nlm.nih.gov/pubmed/37835561
http://dx.doi.org/10.3390/cancers15194867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571707/
https://www.ncbi.nlm.nih.gov/pubmed/37835561
http://dx.doi.org/10.3390/cancers15194867

Ejemplares similares